.png)
Chronic Myelogenous Leukemia Treatment Market By Type Of Treatment and Test - Global Industry Analysis And Forecast To 2027
Published On : November 2018 Pages : 180 Category: Pharmaceuticals Report Code : HC111673
SEGMENTS & REGIONS:
- Regions: North America, Europe, Asia- Pacific, Latin America, Middle East & Africa
Chronic Myelogenous Leukemia Treatment Market By Type Of Treatment (Symptomatic Treatment and Disease Specific Treatment), Drug Type (Generic and Branded) and Test (Retail Pharmacies, Hospital Pharmacies and Specialty Pharmacies) - Global Industry Analysis And Forecast To 2027
Industry Outlook
Chronic Myelogenous Leukemia (CML) is also known as Chronic Myeloid Leukemia, is a type of cancer that affects certain blood forming cells in the bone marrow. In Chronic Myelogenous Leukemia some genetic change takes place in the myeloid cells, cells producing platelets, red blood cells & number of white blood cells. The cells grow and start dividing in the bone marrow and the spill in the blood. The growth rate of Chronic Myelogenous Leukemia is slow but can transform in fast growing which can be hard in treatment. Chronic Myelogenous Leukemia is mainly seen in adults but it rarely affects children. Treatment is same for both adults and children. Chronic Myelogenous Leukemia treatment is seeing groth due to; rising number of cases reklated to (CML), advancement in the treatment procedures, increasing R&D in the treatment, etc. Therefore, the Chronic Myelogenous Leukemia Treatment Market is anticipated to expand and has tremendous scope during the forecast period. The global Chronic Myelogenous Leukemia Treatment Market anticipated to flourish in the future by growing at a significantly higher CAGR.
Market Segmentation
The global Chronic Myelogenous Leukemia Treatment Market is based on segment, by Type Of Treatment the market is segmented into Symptomatic Treatment and Disease Specific Treatment, by Drug Type the market is segmented into Generic and Branded, and by Distribution Channel the market is segmented into Retail Pharmacies, Hospital Pharmacies and Specialty Pharmacies.
- Chronic Myelogenous Leukemia Treatment Market, By Type Of Treatment
- Symptomatic Treatment
- Disease Specific Treatment
- Chronic Myelogenous Leukemia Treatment Market, By Drug Type
- Generic
- Branded
- Chronic Myelogenous Leukemia Treatment Market, By Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Specialty Pharmacies
Regional Insights
On a global front, the Chronic Myelogenous Leukemia Treatment Market covers North America (United States, Canada and Mexico), Europe (Germany, UK, France, Russia, Italy, Rest of Europe), Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific), South America (Brazil, Argentina, Columbia, Rest of South America) and Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA).
Chronic Myelogenous Leukemia Treatment Market, By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Columbia
- Rest of South America
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Nigeria
- South Africa
- Rest of MEA
Competitive Analysis
The leading players in the market are Pfizer Inc., Otsuka Pharmaceutical Co. Ltd., Bristol-Myers Squibb, Schering Plough, Stragen Pharma SA, Teva Pharmaceuticals Industries Ltd., Prism Pharmaceuticals, Bio-Path Holdings, Hoffman-La Roche Ltd., Incyte Corporation, Novartis AG and Hospira Inc.. The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and market share of the overall industry.
- Pfizer Inc.
- Otsuka Pharmaceutical Co. Ltd.
- Bristol-Myers Squibb
- Schering Plough
- Stragen Pharma SA
- Teva Pharmaceuticals Industries Ltd.
- Prism Pharmaceuticals
- Bio-Path Holdings
- Hoffman-La Roche Ltd.
- Incyte Corporation
- Novartis AG
- Hospira Inc.
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2017 to 2027?
- What will be the industry market growth from 2017 to 2027?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
o Chronic Myelogenous Leukemia Treatment Market, By Type Of Treatment, Estimates and Forecast, 2017-2027 ($Million)
o Symptomatic Treatment
o Disease Specific Treatment
o Chronic Myelogenous Leukemia Treatment Market, By Distribution Channel, Estimates and Forecast, 2017-2027 ($Million)
o Generic
o Branded
o Chronic Myelogenous Leukemia Treatment Market, By Drug Type, Estimates and Forecast, 2017-2027 ($Million)
o Retail Pharmacies
o Hospital Pharmacies
o Specialty Pharmacies
o Chronic Myelogenous Leukemia Treatment Market, By Region, Estimates and Forecast, 2017-2027 ($Million)
o North America
§ North America Chronic Myelogenous Leukemia Treatment Market, By Country
o U.S. Chronic Myelogenous Leukemia Treatment Market
o Canada Chronic Myelogenous Leukemia Treatment Market
o Mexico Chronic Myelogenous Leukemia Treatment Market
o Europe
§ Europe Chronic Myelogenous Leukemia Treatment Market, By Country
o Germany Chronic Myelogenous Leukemia Treatment Market
o UK Chronic Myelogenous Leukemia Treatment Market
o France Chronic Myelogenous Leukemia Treatment Market
o Russia Chronic Myelogenous Leukemia Treatment Market
o Italy Chronic Myelogenous Leukemia Treatment Market
o Rest of Europe Chronic Myelogenous Leukemia Treatment Market
o Asia-Pacific
§ Asia-Pacific Chronic Myelogenous Leukemia Treatment Market, By Country
o China Chronic Myelogenous Leukemia Treatment Market
o Japan Chronic Myelogenous Leukemia Treatment Market
o South Korea Chronic Myelogenous Leukemia Treatment Market
o India Chronic Myelogenous Leukemia Treatment Market
o Southeast Asia Chronic Myelogenous Leukemia Treatment Market
o Rest of Asia-Pacific Chronic Myelogenous Leukemia Treatment Market
o South America
§ South America Chronic Myelogenous Leukemia Treatment Market, By Country
o Brazil Chronic Myelogenous Leukemia Treatment Market
o Argentina Chronic Myelogenous Leukemia Treatment Market
o Columbia Chronic Myelogenous Leukemia Treatment Market
o Rest of South America Chronic Myelogenous Leukemia Treatment Market
o Middle East and Africa
§ Middle East and Africa Chronic Myelogenous Leukemia Treatment Market, By Country
o Saudi Arabia Chronic Myelogenous Leukemia Treatment Market
o UAE Chronic Myelogenous Leukemia Treatment Market
o Egypt Chronic Myelogenous Leukemia Treatment Market
o Nigeria Chronic Myelogenous Leukemia Treatment Market
o South Africa Chronic Myelogenous Leukemia Treatment Market
o Rest of MEA Chronic Myelogenous Leukemia Treatment Market
Table of Contents
1. Introduction
1.1. Report Description
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market Status and Outlook (2017-2027)
4.1.2. Canada Market Status and Outlook (2017-2027)
4.1.3. Mexico Market Status and Outlook (2017-2027)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market Status and Outlook (2017-2027)
4.2.2. France Market Status and Outlook (2017-2027)
4.2.3. UK Market Status and Outlook (2017-2027)
4.2.4. Russia Market Status and Outlook (2017-2027)
4.2.5. Italy Market Status and Outlook (2017-2027)
4.2.6. Rest of Europe Market Status and Outlook (2017-2027)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market Status and Outlook (2017-2027)
4.3.2. Japan Market Status and Outlook (2017-2027)
4.3.3. Korea Market Status and Outlook (2017-2027)
4.3.4. India Market Status and Outlook (2017-2027)
4.3.5. Southeast Asia Market Status and Outlook (2017-2027)
4.3.6. Rest of Asia-Pacific Market Status and Outlook (2017-2027)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market Status and Outlook (2017-2027)
4.4.2. Argentina Market Status and Outlook (2017-2027)
4.4.3. Columbia Market Status and Outlook (2017-2027)
4.4.4. Rest of South America Market Status and Outlook (2017-2027)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market Status and Outlook (2017-2027)
4.5.2. United Arab Emirates Market Status and Outlook (2017-2027)
4.5.3. Egypt Market Status and Outlook (2017-2027)
4.5.4. Nigeria Market Status and Outlook (2017-2027)
4.5.5. South Africa Market Status and Outlook (2017-2027)
4.5.6. Turkey Market Status and Outlook (2017-2027)
4.5.7. Rest of Middle East and Africa Market Status and Outlook (2017-2027)
5. Chronic Myelogenous Leukemia Treatment Market, By Type Of Treatment
5.1. Introduction
5.2. Global Chronic Myelogenous Leukemia Treatment Revenue and Market Share by Type Of Treatment (2017-2027)
5.2.1. Global Chronic Myelogenous Leukemia Treatment Revenue and Revenue Share by Type Of Treatment (2017-2027)
5.3. Symptomatic Treatment
5.3.1. Global Symptomatic Treatment Revenue and Growth Rate (2017-2027)
5.4. Disease Specific Treatment
5.4.1. Global Disease Specific Treatment Revenue and Growth Rate (2017-2027)
6. Chronic Myelogenous Leukemia Treatment Market, By Drug Type
6.1. Introduction
6.2. Global Chronic Myelogenous Leukemia Treatment Revenue and Market Share by Drug Type (2017-2027)
6.2.1. Global Chronic Myelogenous Leukemia Treatment Revenue and Revenue Share by Drug Type (2017-2027)
6.3. Generic
6.3.1. Global Generic Revenue and Growth Rate (2017-2027)
6.4. Branded
6.4.1. Global Branded Revenue and Growth Rate (2017-2027)
7. Chronic Myelogenous Leukemia Treatment Market, By Distribution Channel
7.1. Introduction
7.2. Global Chronic Myelogenous Leukemia Treatment Revenue and Market Share by Distribution Channel (2017-2027)
7.2.1. Global Chronic Myelogenous Leukemia Treatment Revenue and Revenue Share by Distribution Channel (2017-2027)
7.3. Retail Pharmacies
7.3.1. Global Retail Pharmacies Revenue and Growth Rate (2017-2027)
7.4. Hospital Pharmacies
7.4.1. Global Hospital Pharmacies Revenue and Growth Rate (2017-2027)
7.5. Specialty Pharmacies
7.5.1. Global Specialty Pharmacies Revenue and Growth Rate (2017-2027)
8. Chronic Myelogenous Leukemia Treatment Market, By Region
8.1. Introduction
8.2. Global Chronic Myelogenous Leukemia Treatment Revenue and Market Share by Regions
8.2.1. Global Chronic Myelogenous Leukemia Treatment Revenue by Regions (2017-2027)
8.3. North America Chronic Myelogenous Leukemia Treatment by Countries
8.3.1. North America Chronic Myelogenous Leukemia Treatment Revenue and Growth Rate (2017-2027)
8.3.2. North America Chronic Myelogenous Leukemia Treatment Revenue (Million USD) by Countries (2017-2027)
8.3.3. United States
8.3.3.1. United States Chronic Myelogenous Leukemia Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
8.3.4. Canada
8.3.4.1. Canada Chronic Myelogenous Leukemia Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
8.3.5. Mexico
8.3.5.1. Mexico Chronic Myelogenous Leukemia Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
8.4. Europe Chronic Myelogenous Leukemia Treatment by Countries
8.4.1. Europe Chronic Myelogenous Leukemia Treatment Revenue and Growth Rate (2017-2027)
8.4.2. Europe Chronic Myelogenous Leukemia Treatment Revenue (Million USD) by Countries (2017-2027)
8.4.3. Germany
8.4.3.1. Germany Chronic Myelogenous Leukemia Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.4. France
8.4.4.1. France Chronic Myelogenous Leukemia Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.5. UK
8.4.5.1. UK Chronic Myelogenous Leukemia Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.6. Russia
8.4.6.1. Russia Chronic Myelogenous Leukemia Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.7. Italy
8.4.7.1. Italy Chronic Myelogenous Leukemia Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.8. Rest of Europe
8.4.8.1. Rest of Europe Chronic Myelogenous Leukemia Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
8.5. Asia-Pacific Chronic Myelogenous Leukemia Treatment by Countries
8.5.1. Asia-Pacific Chronic Myelogenous Leukemia Treatment Revenue and Growth Rate (2017-2027)
8.5.2. Asia-Pacific Chronic Myelogenous Leukemia Treatment Revenue (Million USD) by Countries (2017-2027)
8.5.3. China
8.5.3.1. China Chronic Myelogenous Leukemia Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.4. Japan
8.5.4.1. Japan Chronic Myelogenous Leukemia Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.5. Korea
8.5.5.1. Korea Chronic Myelogenous Leukemia Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.6. India
8.5.6.1. India Chronic Myelogenous Leukemia Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.7. Southeast Asia
8.5.7.1. Southeast Asia Chronic Myelogenous Leukemia Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.8. Rest of Asia-Pacific
8.5.8.1. Rest of Asia-Pacific Chronic Myelogenous Leukemia Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
8.6. South America Chronic Myelogenous Leukemia Treatment by Countries
8.6.1. South America Chronic Myelogenous Leukemia Treatment Revenue and Growth Rate (2017-2027)
8.6.2. South America Chronic Myelogenous Leukemia Treatment Revenue (Million USD) by Countries (2017-2027)
8.6.3. Brazil
8.6.3.1. Brazil Chronic Myelogenous Leukemia Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
8.6.4. Argentina
8.6.4.1. Argentina Chronic Myelogenous Leukemia Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
8.6.5. Columbia
8.6.5.1. Columbia Chronic Myelogenous Leukemia Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
8.6.6. Rest of South America
8.6.6.1. Rest of South America Chronic Myelogenous Leukemia Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
8.7. Middle East and Africa Chronic Myelogenous Leukemia Treatment by Countries
8.7.1. Middle East and Africa Chronic Myelogenous Leukemia Treatment Revenue and Growth Rate (2017-2027)
8.7.2. Middle East and Africa Chronic Myelogenous Leukemia Treatment Revenue (Million USD) by Countries (2017-2027)
8.7.3. Saudi Arabia
8.7.3.1. Saudi Arabia Chronic Myelogenous Leukemia Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.4. United Arab Emirates
8.7.4.1. United Arab Emirates Chronic Myelogenous Leukemia Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.5. Egypt
8.7.5.1. Egypt Chronic Myelogenous Leukemia Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.6. Nigeria
8.7.6.1. Nigeria Chronic Myelogenous Leukemia Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.7. South Africa
8.7.7.1. South Africa Chronic Myelogenous Leukemia Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.8. Turkey
8.7.8.1. Turkey Chronic Myelogenous Leukemia Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.9. Rest of Middle East and Africa
8.7.9.1. Rest of Middle East and Africa Chronic Myelogenous Leukemia Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
9. Company Profiles
9.1. Pfizer Inc.
9.1.1. Business Overview
9.1.2. Service Portfolio
9.1.3. Strategic Developments
9.1.4. Revenue and Market Share
9.2. Otsuka Pharmaceutical Co. Ltd.
9.2.1. Business Overview
9.2.2. Service Portfolio
9.2.3. Strategic Developments
9.2.4. Revenue and Market Share
9.3. Bristol-Myers Squibb
9.3.1. Business Overview
9.3.2. Service Portfolio
9.3.3. Strategic Developments
9.3.4. Revenue and Market Share
9.4. Schering Plough
9.4.1. Business Overview
9.4.2. Service Portfolio
9.4.3. Strategic Developments
9.4.4. Revenue and Market Share
9.5. Stragen Pharma SA
9.5.1. Business Overview
9.5.2. Service Portfolio
9.5.3. Strategic Developments
9.5.4. Revenue and Market Share
9.6. Teva Pharmaceuticals Industries Ltd.
9.6.1. Business Overview
9.6.2. Service Portfolio
9.6.3. Strategic Developments
9.6.4. Revenue and Market Share
9.7. Prism Pharmaceuticals
9.7.1. Business Overview
9.7.2. Service Portfolio
9.7.3. Strategic Developments
9.7.4. Revenue and Market Share
9.8. Bio-Path Holdings
9.8.1. Business Overview
9.8.2. Service Portfolio
9.8.3. Strategic Developments
9.8.4. Revenue and Market Share
9.9. Hoffman-La Roche Ltd.
9.9.1. Business Overview
9.9.2. Service Portfolio
9.9.3. Strategic Developments
9.9.4. Revenue and Market Share
9.10. Incyte Corporation
9.10.1. Business Overview
9.10.2. Service Portfolio
9.10.3. Strategic Developments
9.10.4. Revenue and Market Share
9.11. Novartis AG
9.11.1. Business Overview
9.11.2. Service Portfolio
9.11.3. Strategic Developments
9.11.4. Revenue and Market Share
9.12. Hospira Inc.
9.12.1. Business Overview
9.12.2. Service Portfolio
9.12.3. Strategic Developments
9.12.4. Revenue and Market Share
10. Global Chronic Myelogenous Leukemia Treatment Market Competition, by Manufacturer
10.1. Global Chronic Myelogenous Leukemia Treatment Revenue and Market Share by Manufacturer (2017-2017)
10.2. Global Chronic Myelogenous Leukemia Treatment Price By Region (2017-2017)
10.3. Top 5 Chronic Myelogenous Leukemia Treatment Manufacturer Market Share
10.4. Market Competition Trend
11. Chronic Myelogenous Leukemia Treatment Market Forecast (2017-2027)
11.1. Global Chronic Myelogenous Leukemia Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
11.2. Chronic Myelogenous Leukemia Treatment Market Forecast by Regions (2017-2027)
11.2.1. North America Chronic Myelogenous Leukemia Treatment Market Forecast (2017-2027)
11.2.1.1. United States Chronic Myelogenous Leukemia Treatment Market Forecast (2017-2027)
11.2.1.2. Canada Chronic Myelogenous Leukemia Treatment Market Forecast (2017-2027)
11.2.1.3. Mexico Chronic Myelogenous Leukemia Treatment Market Forecast (2017-2027)
11.2.2. Europe Chronic Myelogenous Leukemia Treatment Market Forecast (2017-2027)
11.2.2.1. Germany Chronic Myelogenous Leukemia Treatment Market Forecast (2017-2027)
11.2.2.2. France Chronic Myelogenous Leukemia Treatment Market Forecast (2017-2027)
11.2.2.3. UK Chronic Myelogenous Leukemia Treatment Market Forecast (2017-2027)
11.2.2.4. Russia Chronic Myelogenous Leukemia Treatment Market Forecast (2017-2027)
11.2.2.5. Italy Chronic Myelogenous Leukemia Treatment Market Forecast (2017-2027)
11.2.2.6. Rest of Europe Chronic Myelogenous Leukemia Treatment Market Forecast (2017-2027)
11.2.3. Asia-Pacific Chronic Myelogenous Leukemia Treatment Market Forecast (2017-2027)
11.2.3.1. China Chronic Myelogenous Leukemia Treatment Market Forecast (2017-2027)
11.2.3.2. Japan Chronic Myelogenous Leukemia Treatment Market Forecast (2017-2027)
11.2.3.3. Korea Chronic Myelogenous Leukemia Treatment Market Forecast (2017-2027)
11.2.3.4. India Chronic Myelogenous Leukemia Treatment Market Forecast (2017-2027)
11.2.3.5. Southeast Asia Chronic Myelogenous Leukemia Treatment Market Forecast (2017-2027)
11.2.3.6. Rest of Asia-Pacific Chronic Myelogenous Leukemia Treatment Market Forecast (2017-2027)
11.2.4. South America Chronic Myelogenous Leukemia Treatment Market Forecast (2017-2027)
11.2.4.1. Brazil Chronic Myelogenous Leukemia Treatment Market Forecast (2017-2027)
11.2.4.2. Argentina Chronic Myelogenous Leukemia Treatment Market Forecast (2017-2027)
11.2.4.3. Columbia Chronic Myelogenous Leukemia Treatment Market Forecast (2017-2027)
11.2.4.4. Rest of South America Chronic Myelogenous Leukemia Treatment Market Forecast (2017-2027)
11.2.5. Middle East and Africa Chronic Myelogenous Leukemia Treatment Market Forecast (2017-2027)
11.2.5.1. Saudi Arabia Chronic Myelogenous Leukemia Treatment Market Forecast (2017-2027)
11.2.5.2. United Arab Emirates Chronic Myelogenous Leukemia Treatment Market Forecast (2017-2027)
11.2.5.3. Egypt Chronic Myelogenous Leukemia Treatment Market Forecast (2017-2027)
11.2.5.4. Nigeria Chronic Myelogenous Leukemia Treatment Market Forecast (2017-2027)
11.2.5.5. South Africa Chronic Myelogenous Leukemia Treatment Market Forecast (2017-2027)
11.2.5.6. Turkey Chronic Myelogenous Leukemia Treatment Market Forecast (2017-2027)
11.2.5.7. Rest of Middle East and Africa Chronic Myelogenous Leukemia Treatment Market Forecast (2017-2027)
11.3. Chronic Myelogenous Leukemia Treatment Market Forecast by Type Of Treatment (2017-2027)
11.3.1. Chronic Myelogenous Leukemia Treatment Forecast by Type Of Treatment (2017-2027)
11.3.2. Chronic Myelogenous Leukemia Treatment Market Share Forecast by Type Of Treatment (2017-2027)
11.4. Chronic Myelogenous Leukemia Treatment Market Forecast by Drug Type (2017-2027)
11.4.1. Chronic Myelogenous Leukemia Treatment Forecast by Drug Type (2017-2027)
11.4.2. Chronic Myelogenous Leukemia Treatment Market Share Forecast by Drug Type (2017-2027)
11.5. Chronic Myelogenous Leukemia Treatment Market Forecast by Distribution Channel (2017-2027)
11.5.1. Chronic Myelogenous Leukemia Treatment Forecast by Distribution Channel (2017-2027)
11.5.2. Chronic Myelogenous Leukemia Treatment Market Share Forecast by Distribution Channel (2017-2027)
12. List of Tables and Figures
Figure United States Chronic Myelogenous Leukemia Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Canada Chronic Myelogenous Leukemia Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Mexico Chronic Myelogenous Leukemia Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Germany Chronic Myelogenous Leukemia Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure France Chronic Myelogenous Leukemia Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure UK Chronic Myelogenous Leukemia Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Russia Chronic Myelogenous Leukemia Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Italy Chronic Myelogenous Leukemia Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Europe Chronic Myelogenous Leukemia Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure China Chronic Myelogenous Leukemia Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Japan Chronic Myelogenous Leukemia Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Korea Chronic Myelogenous Leukemia Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure India Chronic Myelogenous Leukemia Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Southeast Asia Chronic Myelogenous Leukemia Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Asia-Pacific Chronic Myelogenous Leukemia Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Brazil Chronic Myelogenous Leukemia Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Argentina Chronic Myelogenous Leukemia Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Columbia Chronic Myelogenous Leukemia Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of South America Chronic Myelogenous Leukemia Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Saudi Arabia Chronic Myelogenous Leukemia Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure United Arab Emirates Chronic Myelogenous Leukemia Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Egypt Chronic Myelogenous Leukemia Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Nigeria Chronic Myelogenous Leukemia Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure South Africa Chronic Myelogenous Leukemia Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Turkey Chronic Myelogenous Leukemia Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Middle East and Africa Chronic Myelogenous Leukemia Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Table Global Chronic Myelogenous Leukemia Treatment Revenue and Revenue Share by Type Of Treatment (2017-2027)
Figure Global Symptomatic Treatment Revenue and Growth Rate (2017-2027)
Figure Global Disease Specific Treatment Revenue and Growth Rate (2017-2027)
Table Global Chronic Myelogenous Leukemia Treatment Revenue and Revenue Share by Drug Type (2017-2027)
Figure Global Generic Revenue and Growth Rate (2017-2027)
Figure Global Branded Revenue and Growth Rate (2017-2027)
Table Global Chronic Myelogenous Leukemia Treatment Revenue and Revenue Share by Distribution Channel (2017-2027)
Figure Global Retail Pharmacies Revenue and Growth Rate (2017-2027)
Figure Global Hospital Pharmacies Revenue and Growth Rate (2017-2027)
Figure Global Specialty Pharmacies Revenue and Growth Rate (2017-2027)
Table Global Chronic Myelogenous Leukemia Treatment Revenue by Regions (2017-2027)
Figure North America Chronic Myelogenous Leukemia Treatment Growth Rate (2017-2027)
Figure North America Chronic Myelogenous Leukemia Treatment Revenue and Growth Rate (2017-2027)
Figure North America Chronic Myelogenous Leukemia Treatment by Countries (2017-2027)
Figure North America Chronic Myelogenous Leukemia Treatment Revenue (Million USD) by Countries (2017-2027)
Figure United States Chronic Myelogenous Leukemia Treatment Growth Rate (2017-2027)
Figure United States Chronic Myelogenous Leukemia Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
Figure Canada Chronic Myelogenous Leukemia Treatment Growth Rate (2017-2027)
Figure Canada Chronic Myelogenous Leukemia Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
Figure Mexico Chronic Myelogenous Leukemia Treatment Growth Rate (2017-2027)
Figure Mexico Chronic Myelogenous Leukemia Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
Figure Europe Chronic Myelogenous Leukemia Treatment Growth Rate (2017-2027)
Figure Europe Chronic Myelogenous Leukemia Treatment Revenue and Growth Rate (2017-2027)
Figure Europe Chronic Myelogenous Leukemia Treatment by Countries (2017-2027)
Figure Europe Chronic Myelogenous Leukemia Treatment Revenue (Million USD) by Countries (2017-2027)
Figure Germany Chronic Myelogenous Leukemia Treatment Growth Rate (2017-2027)
Figure Germany Chronic Myelogenous Leukemia Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
Figure France Chronic Myelogenous Leukemia Treatment Growth Rate (2017-2027)
Figure France Chronic Myelogenous Leukemia Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
Figure UK Chronic Myelogenous Leukemia Treatment Growth Rate (2017-2027)
Figure UK Chronic Myelogenous Leukemia Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
Figure Russia Chronic Myelogenous Leukemia Treatment Growth Rate (2017-2027)
Figure Russia Chronic Myelogenous Leukemia Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
Figure Italy Chronic Myelogenous Leukemia Treatment Growth Rate (2017-2027)
Figure Italy Chronic Myelogenous Leukemia Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
Figure Rest of Europe Chronic Myelogenous Leukemia Treatment Growth Rate (2017-2027)
Figure Rest of Europe Chronic Myelogenous Leukemia Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
Figure Asia-Pacific Chronic Myelogenous Leukemia Treatment Growth Rate (2017-2027)
Figure Asia-Pacific Chronic Myelogenous Leukemia Treatment Revenue and Growth Rate (2017-2027)
Figure Asia-Pacific Chronic Myelogenous Leukemia Treatment by Countries (2017-2027)
Figure Asia-Pacific Chronic Myelogenous Leukemia Treatment Revenue (Million USD) by Countries (2017-2027)
Figure China Chronic Myelogenous Leukemia Treatment Growth Rate (2017-2027)
Figure China Chronic Myelogenous Leukemia Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
Figure Japan Chronic Myelogenous Leukemia Treatment Growth Rate (2017-2027)
Figure Japan Chronic Myelogenous Leukemia Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
Figure Korea Chronic Myelogenous Leukemia Treatment Growth Rate (2017-2027)
Figure Korea Chronic Myelogenous Leukemia Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
Figure India Chronic Myelogenous Leukemia Treatment Growth Rate (2017-2027)
Figure India Chronic Myelogenous Leukemia Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
Figure Southeast Asia Chronic Myelogenous Leukemia Treatment Growth Rate (2017-2027)
Figure Southeast Asia Chronic Myelogenous Leukemia Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
Figure Rest of Asia-Pacific Chronic Myelogenous Leukemia Treatment Growth Rate (2017-2027)
Figure Rest of Asia-Pacific Chronic Myelogenous Leukemia Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
Figure South America Chronic Myelogenous Leukemia Treatment Growth Rate (2017-2027)
Figure South America Chronic Myelogenous Leukemia Treatment Revenue and Growth Rate (2017-2027)
Figure South America Chronic Myelogenous Leukemia Treatment by Countries (2017-2027)
Figure South America Chronic Myelogenous Leukemia Treatment Revenue (Million USD) by Countries (2017-2027)
Figure Brazil Chronic Myelogenous Leukemia Treatment Growth Rate (2017-2027)
Figure Brazil Chronic Myelogenous Leukemia Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
Figure Argentina Chronic Myelogenous Leukemia Treatment Growth Rate (2017-2027)
Figure Argentina Chronic Myelogenous Leukemia Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
Figure Columbia Chronic Myelogenous Leukemia Treatment Growth Rate (2017-2027)
Figure Columbia Chronic Myelogenous Leukemia Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
Figure Rest of South America Chronic Myelogenous Leukemia Treatment Growth Rate (2017-2027)
Figure Rest of South America Chronic Myelogenous Leukemia Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
Figure Middle East and Africa Chronic Myelogenous Leukemia Treatment Growth Rate (2017-2027)
Figure Middle East and Africa Chronic Myelogenous Leukemia Treatment Revenue and Growth Rate (2017-2027)
Figure Middle East and Africa Chronic Myelogenous Leukemia Treatment by Countries (2017-2027)
Figure Middle East and Africa Chronic Myelogenous Leukemia Treatment Revenue (Million USD) by Countries (2017-2027)
Figure Saudi Arabia Chronic Myelogenous Leukemia Treatment Growth Rate (2017-2027)
Figure Saudi Arabia Chronic Myelogenous Leukemia Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
Figure United Arab Emirates Chronic Myelogenous Leukemia Treatment Growth Rate (2017-2027)
Figure United Arab Emirates Chronic Myelogenous Leukemia Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
Figure Egypt Chronic Myelogenous Leukemia Treatment Growth Rate (2017-2027)
Figure Egypt Chronic Myelogenous Leukemia Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
Figure Nigeria Chronic Myelogenous Leukemia Treatment Growth Rate (2017-2027)
Figure Nigeria Chronic Myelogenous Leukemia Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
Figure South Africa Chronic Myelogenous Leukemia Treatment Growth Rate (2017-2027)
Figure South Africa Chronic Myelogenous Leukemia Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
Figure Turkey Chronic Myelogenous Leukemia Treatment Growth Rate (2017-2027)
Figure Turkey Chronic Myelogenous Leukemia Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
Figure Rest of Middle East and Africa Chronic Myelogenous Leukemia Treatment Growth Rate (2017-2027)
Figure Rest of Middle East and Africa Chronic Myelogenous Leukemia Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
Table Pfizer Inc. Chronic Myelogenous Leukemia Treatment Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Otsuka Pharmaceutical Co. Ltd. Chronic Myelogenous Leukemia Treatment Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Bristol-Myers Squibb Chronic Myelogenous Leukemia Treatment Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Schering Plough Chronic Myelogenous Leukemia Treatment Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Stragen Pharma SA Chronic Myelogenous Leukemia Treatment Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Teva Pharmaceuticals Industries Ltd. Chronic Myelogenous Leukemia Treatment Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Prism Pharmaceuticals Chronic Myelogenous Leukemia Treatment Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Bio-Path Holdings Chronic Myelogenous Leukemia Treatment Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Hoffman-La Roche Ltd. Chronic Myelogenous Leukemia Treatment Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Incyte Corporation Chronic Myelogenous Leukemia Treatment Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Novartis AG Chronic Myelogenous Leukemia Treatment Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Hospira Inc. Chronic Myelogenous Leukemia Treatment Price, Revenue, Gross Margin and Market Share (2017-2017)
Figure Global Chronic Myelogenous Leukemia Treatment Market Share by Manufacturer
Figure Global Chronic Myelogenous Leukemia Treatment Revenue and Market Share by Manufacturer
Table Global Chronic Myelogenous Leukemia Treatment Price by Region (2017-2017)
Figure Top 5 Chronic Myelogenous Leukemia Treatment Manufacturer (Revenue) Market Share
Figure Market Competition Trend
Figure Global Chronic Myelogenous Leukemia Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
Table Chronic Myelogenous Leukemia Treatment Market Forecast by Regions (2017-2027)
Figure North America Chronic Myelogenous Leukemia Treatment Market Forecast (2017-2027)
Figure United States Chronic Myelogenous Leukemia Treatment Market Forecast (2017-2027)
Figure Canada Chronic Myelogenous Leukemia Treatment Market Forecast (2017-2027)
Figure Mexico Chronic Myelogenous Leukemia Treatment Market Forecast (2017-2027)
Figure Europe Chronic Myelogenous Leukemia Treatment Market Forecast (2017-2027)
Figure Germany Chronic Myelogenous Leukemia Treatment Market Forecast (2017-2027)
Figure France Chronic Myelogenous Leukemia Treatment Market Forecast (2017-2027)
Figure UK Chronic Myelogenous Leukemia Treatment Market Forecast (2017-2027)
Figure Russia Chronic Myelogenous Leukemia Treatment Market Forecast (2017-2027)
Figure Italy Chronic Myelogenous Leukemia Treatment Market Forecast (2017-2027)
Figure Rest of Europe Chronic Myelogenous Leukemia Treatment Market Forecast (2017-2027)
Figure Asia-Pacific Chronic Myelogenous Leukemia Treatment Market Forecast (2017-2027)
Figure China Chronic Myelogenous Leukemia Treatment Market Forecast (2017-2027)
Figure Japan Chronic Myelogenous Leukemia Treatment Market Forecast (2017-2027)
Figure Korea Chronic Myelogenous Leukemia Treatment Market Forecast (2017-2027)
Figure India Chronic Myelogenous Leukemia Treatment Market Forecast (2017-2027)
Figure Southeast Asia Chronic Myelogenous Leukemia Treatment Market Forecast (2017-2027)
Figure Rest of Asia-Pacific Chronic Myelogenous Leukemia Treatment Market Forecast (2017-2027)
Figure South America Chronic Myelogenous Leukemia Treatment Market Forecast (2017-2027)
Figure Brazil Chronic Myelogenous Leukemia Treatment Market Forecast (2017-2027)
Figure Argentina Chronic Myelogenous Leukemia Treatment Market Forecast (2017-2027)
Figure Columbia Chronic Myelogenous Leukemia Treatment Market Forecast (2017-2027)
Figure Rest of South America Chronic Myelogenous Leukemia Treatment Market Forecast (2017-2027)
Figure Middle East and Africa Chronic Myelogenous Leukemia Treatment Market Forecast (2017-2027)
Figure Saudi Arabia Chronic Myelogenous Leukemia Treatment Market Forecast (2017-2027)
Figure United Arab Emirates Chronic Myelogenous Leukemia Treatment Market Forecast (2017-2027)
Figure Egypt Chronic Myelogenous Leukemia Treatment Market Forecast (2017-2027)
Figure Nigeria Chronic Myelogenous Leukemia Treatment Market Forecast (2017-2027)
Figure South Africa Chronic Myelogenous Leukemia Treatment Market Forecast (2017-2027)
Figure Turkey Chronic Myelogenous Leukemia Treatment Market Forecast (2017-2027)
Figure Rest of Middle East and Africa Chronic Myelogenous Leukemia Treatment Market Forecast (2017-2027)
Figure Global Chronic Myelogenous Leukemia Treatment Forecast by Type Of Treatment (2017-2027)
Figure Global Chronic Myelogenous Leukemia Treatment Market Share Forecast by Type Of Treatment (2017-2027)
Figure Global Chronic Myelogenous Leukemia Treatment Forecast by Type Of Treatment (2017-2027)
Figure Global Chronic Myelogenous Leukemia Treatment Forecast by Drug Type (2017-2027)
Figure Global Chronic Myelogenous Leukemia Treatment Market Share Forecast by Drug Type (2017-2027)
Figure Global Chronic Myelogenous Leukemia Treatment Forecast by Drug Type (2017-2027)
Figure Global Chronic Myelogenous Leukemia Treatment Forecast by Distribution Channel (2017-2027)
Figure Global Chronic Myelogenous Leukemia Treatment Market Share Forecast by Distribution Channel (2017-2027)
Figure Global Chronic Myelogenous Leukemia Treatment Forecast by Distribution Channel (2017-2027)
Please Note: Data related to the Companies are subject to Availability.
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|